L-DOPA: From a biologically inactive amino acid to a successful therapeutic agent: Historical review article

Amino Acids

Volumn 23, Issue 1-3, 2002, Pages 65-70

  Hornykiewicz, O ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Dopamine; Dopamine replacement; L Dopa history; L Dopa pharmacology; L Dopa therapy; Parkinson's disease

Indexed keywords

AMINE; AMINO ACID; AROMATIC LEVO AMINO ACID DECARBOXYLASE; CATECHOLAMINE DERIVATIVE; DOPAMINE; ENZYME; HYPERTENSIVE FACTOR; INSULIN; LEVODOPA; NEUROTRANSMITTER; RESERPINE;

ART; ARTERIAL PRESSURE; BEAN; BRAIN TISSUE; CLINICAL PRACTICE; CONFERENCE PAPER; DECARBOXYLATION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG ISOLATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG STORAGE; ENZYME ACTIVITY; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; ISOMERISM; NONHUMAN; PARKINSON DISEASE; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; RABBIT; RACEMIC MIXTURE; SEEDLING; SUBSTITUTION THERAPY; VICIA FABA;

ANIMALS; ANTIPARKINSON AGENTS; BRAIN; CATECHOLAMINES; DOPAMINE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; LEVODOPA; MOLECULAR STRUCTURE; PARKINSON DISEASE;

ANIMALIA; ORYCTOLAGUS CUNICULUS; PHASEOLUS (ANGIOSPERM); VICIA; VICIA FABA;

EID: 0036391727     PISSN: 09394451     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00726-001-0111-9     Document Type: Conference Paper

References (57)

1. Barbeau A, Murphy GF, Sourkes TL (1961) Excretion of dopamine in diseases of basal ganglia. Science 133: 1706-1707
2. Barbeau A, Sourkes TL, Murphy GF (1962) Les catécholamines dans la maladie de Parkinson. In: de Ajuriaguerra J (ed) Monoamines et système nerveux central. Georg & Cie SA, Geneva, pp 247-262
3. Barger G, Dale HH (1910) Chemical structure and sympathomimetic action of amines. J Physiol 41: 19-59
4. Bernheimer H (1964) Über das Vorkommen von Katecholaminen und von 3,4-Dihydroxyphenylalanin (Dopa) im Auge. Naunyn-Schmiedeberg's Arch Exp Path Pharmak 247: 202-213
5. Bertler A, Rosengren E (1959) Occurrence and distribution of dopamine in brain and other tissues. Experientia 15: 10-11
6. Bertler A, Rosengren E (1966) Possible role of brain dopamine. Pharmacol Rev 18: 769-773
7. Bing RJ (1941) The formation of hydroxytyramine by extracts of renal cortex and by perfused kidneys. Am J Physiol 132: 497-503
8. Bing RJ, Zucker MB (1941) Renal hypertension produced by an amino acid. J Exp Med 74: 235-245
9. Birkmayer W, Hornykiewicz O (1961) Der L-3,4-Dioxyphenylalanin (= DOPA) - Effekt bei der Parkinson-Akinese. Wien Klin Wochenschr 73: 787-788
10. Blaschko H (1939) The specific action of L-dopa decarboxylase. J Physiol 96: 50P
11. Bloch B (1916) Chemische Untersuchungen über das spezifische pigmentbildende Ferment der Haut, die Dopaoxydase. Hoppe-Seyler's Zeitschr Physiol Chemie 98: 226-254
12. Burn JH, Rand MJ (1960) The effect of precursors of noradrenaline on the response to tyramine and sympathetic stimulation. Br J Pharmacol 15: 47-55
13. Calne DB, Teychenne PF, Claveria LE, Eastman R, Greenacre JK, Petrie A (1974) Bromocriptine in parkinsonism. Br Med J 4: 442-444
14. Carlsson A (1959) The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol Rev 11: 490-493
15. Carlsson A, Lindqvist M, Magnusson T (1957) 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature London 180: 1200
16. Carlsson A, Lindqvist M, Magnusson T, Waldeck B (1958) On the presence of 3-hydroxytyramine in brain. Science 127: 471
17. Cotzias GC, Van Woert MH, Schiffer LM (1967) Aromatic amino acids and modification of parkinsonism. N Engl J Med 276: 374-379
18. 6. Klin Wochenschr 38: 120-123
19. 14 (dopa) to norepinephrine by bovine adrenal medullary homogenates. J Pharmacol Exp Ther 117: 208-212
20. Ehringer H, Hornykiewicz O (1960) Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin Wochenschr 38: 1236-1239
21. Fisher A, Biggs CS, Eradiri O, Starr MS (1999) Dual effects of L-3,4-dihydroxyphenylalanine on aromatic L-amino acid decarboxylase, dopamine release and motor stimulation in the reserpine-treated rat: evidence that behaviour is dopamine independent. Neuroscience 95: 97-111
22. Funk C (1911) Synthesis of dl-3:4-dihydroxyphenylalanine. J Chem Soc 99: 554-557
23. Goodall McG (1950) Dihydroxyphenylalanine and hydroxytyramine in mammalian suprarenals. Acta Chem Scand 4: 550
24. Guggenheim M (1913) Dioxyphenylalanin, eine neue Aminosäure aus Vicia faba. Hoppe-Seyler's Zeitschr Physiol Chem 88: 276-284
25. Hagen P, Welch AD (1956) The adrenal medulla and the biosynthesis of pressor amines. Recent Progr Hormone Res 12: 27-44
26. Hasama B (1930) Beiträge zur Erforschung der Bedeutung der chemischen Konfiguration für die pharmakologischen Wirkungen der adrenalinähnlichen Stoffe. Arch Exp Path Pharmak 153: 161-186
27. Hirai K, Gondo K (1927) Über Dopa-Hyperglykämie. Biochem Zeitschr 120: 92-100
28. Holtz P (1939) Dopadecarboxylase. Naturwissenschaften 27: 724-725
29. Holtz P (1950) Über die sympathicomimetische Wirksamkeit von Gehirnextrakten. Acta Physiol Scand 20: 354-362
30. Holtz P, Credner K (1942) Die enzymatische Entstehung von Oxytyramin im Organismus und die physiologische Bedeutung der Dopadecarboxylase. Naunyn-Schmiedeberg's Arch Exp Path Pharmak 200: 256-288
31. Holtz P, Heise R, Lüdtke K (1938) Fermentativer Abbau von L-Dioxyphenylalanin (Dopa) durch Niere. Naunyn-Schmiedeberg's Arch Exp Path Pharmak 191: 87-118
32. Hornykiewicz O (1958) The action of dopamine on the arterial blood pressure of the guinea pig. Br J Pharmacol 13: 91-94
33. Hornykiewicz O (1992) From dopamine to Parkinson's disease: a personal research record. In: Samson F, Adelman G (eds) The neurosciences: paths of discovery II. Birkhäuser, Boston, pp 125-146
34. Hornykiewicz O (1994) Levodopa in the 1960s: starting point Vienna. In: Poewe W, Lees AJ (eds) 20 Years of Madopar - new avenues. Editiones Roche, Basel, pp 11-27
35. Hornykiewicz O (2001) How L-DOPA was discovered as a drug for Parkinson's disease 40 years ago. Wien Klin Wochenschr 113: 855-862
36. Jasper HH (1970) Neurophysiological mechanisms in parkinsonism. In: Barbeau A, McDowell FH (eds) L-Dopa and parkinsonism. FA Davies, Philadelphia, pp 408-411
37. Krnjevic K, Phillis JW (1963) Actions of certain amines on cerebral cortical neurones. Br J Pharmacol 20: 471-490
38. Lloyd KG, Davidson L, Hornykiewicz O (1975) The neurochemistry of Parkinson's disease: effect of L-dopa therapy. J Pharmacol Exp Ther 195: 453-464
39. Misu Y, Goshima Y (1993) Is L-dopa an endogenous neurotransmitter? Trends Pharmacol Sci 14: 119-123
40. Misu Y, Ueda H, Goshima Y (1995) Neurotransmitter-like actions of L-DOPA. Adv Pharmacol 32: 427-459
41. Monnier M, Tissot R (1958) Action de la réserpine et de ses médiateurs (5-hydroxytryptophan - sérotonine et dopa -noradrénaline) sur le comportement et le cerveau du lapin. Helv Physiol Acta 16: 255-267
42. Montagu KA (1957) Catechol compounds in rat tissues and in brains of different animals. Nature London 180: 244-245
43. Oster KA, Sorkin SZ (1942) Effects of intravenous injections of L-dopa upon blood pressure. Proc Soc Exp Biol Med 51: 67-70
44. Page EW, Reed R (1945) Hypertensive effect of L-dopa and related compounds in the rat. Am J Physiol 143: 122-125
45. Raab W, Gigee W (1951) Concentration and distribution of "encephalin" in the brain of humans and animals. Proc Soc Exp Biol Med 76: 97-100
46. Rothballer AB (1959) The effects of catecholamines on the central nervous system. Pharmacol Rev 11: 494-547
47. Sano I, Gamo T, Kakimoto Y, Taniguchi K, Takesada M, Nishinuma K (1959) Distribution of catechol compounds in human brain. Biochim Biophys Acta 32: 586-587
48. Schroeder HA (1942) Arterial hypertension in rats. J Exp Med 75: 513-526
49. Sourkes TL (1961) Formation of dopamine in vivo: relation to the function of the basal ganglia. Rev Canad Biol 20: 186-196
50. Sourkes TL, Heneage P, Trano Y (1952) Enzymatic decarboxylation of isomers and derivatives of dihydroxyphenylalanine. Arch Biochem Biophys 40: 185-193
51. Van Arman CG (1951) Amino acids and amines as precursors of epinephrine. Am J Physiol 164: 476-479
52. Vogt M (1954) The concentration of sympathin in different parts of the central nervous system under normal conditions and after the administration of drugs. J Physiol 123: 451-481
53. Vogt M (1973) Functional aspects of the role of catecholamines in the central nervous system. Br Med Bull 29: 168-172
54. Ward AA (1970) Physiological implications in the dyskinesias. In: Barbeau A, McDowell FH (eds) L-Dopa and parkinsonism. FA Davies, Philadelphia, pp 151-159
55. Weil-Malherbe H (1956) Phaeochromocytoma. Catechols in urine and tumour tissue. Lancet ii: 282-284
56. Weil-Malherbe H, Bone AD (1957) Intracellular distribution of catecholamines in the brain. Nature London 180: 1050-1051
57. Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM (1969) Treatment of parkinsonism with levodopa. Arch Neurol 21: 343-354